Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs

References

• Aarons L., Chan E., Rowland M., Breckenridge A., Serlin M. Relationship between vitamin K-dependent clotting factors and warfarin anticoagulation at steady-state. Acta Pharmacologica et Toxicologica (Copenhagen) 1986; 59: 55
   Google Scholar
• Abbrecht P. H., O'Leary T. J., Behrendt D. M. Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model. Clinical Pharmacology and Therapeutics 1982; 32: 129–136
   PubMed Web of Science ®Google Scholar
• Akaike H. An information criterion (AIC). Mathematical Sciences 1976; 14: 5–9
   Google Scholar
• Bara L., Billaud E., Gramond G., Kher A., Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thrombosis Research 1985; 39: 631–636
   PubMed Web of Science ®Google Scholar
• Bara L., Leizorovicz A., Picolet H., Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin (LMWH) or unfractionated heparin. Thrombosis Research 1992; 65: 641–650
   PubMed Web of Science ®Google Scholar
• Benchekroun S., Eychenne B., Mericq O., Colombari A., Douste-Blazy P., Barret A., Sie P., Boneu B. Heparin half-life and sensitivity in patients affected by deep vein thrombosis. European Journal of Clinical Investigation 1986; 16: 536–539
   PubMed Web of Science ®Google Scholar
• Boneu B., Buchman M. R., Caronobe C., Gabaig A. M., Dupony D., Sie P., Hirsh J. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thrombosis Research 1987; 46: 845–853
   PubMed Web of Science ®Google Scholar
• Boneu B., Dol F., Caronobe C., Sie P., Houin G. Pharmacokinetics of heparin and related polysaccharides. Annals of the New York Academy of Sciences 1989; 556: 282–289
   PubMed Web of Science ®Google Scholar
• Briant L., Caronobe C., Saivin S., Sie P., Bayrou B., Boneu B. Unfractionated heparin and CY-216: Pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thrombosis and Haemostasis 1989; 61: 348–353
   PubMed Web of Science ®Google Scholar
• Cutler D. Linear systems analysis in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1978; 6: 265–282
   PubMedGoogle Scholar
• Dawes J., Bara L., Billard E., Samama H. Relationship between biological activity and concentration of a low-molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostatasis 1986; 16: 116–122
   PubMedGoogle Scholar
• De Boer A., Stiekema J. C., Danhof M., Breimer D. D. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of ORG 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. Journal of Clinical Pharmacology 1991; 31: 611–617
   PubMed Web of Science ®Google Scholar
• Estes J. W. The heterogeneity of the anticoagulant response to heparin. Journal of Clinical Pathology 1972; 25: 45–48
   PubMed Web of Science ®Google Scholar
• Gillespie W. R. Noncompartmental versus compartmental modelling in clinical pharmacokinetics. Clinical Pharmacokinetics 1991; 20: 253–262
   PubMed Web of Science ®Google Scholar
• Goldstein A., Aronow L., Kalman S. H. Principles of drug action. The Basis of Pharmacology. Wiley, New York 1974; 82–84
   Google Scholar
• Harenberg J., Gnass A., De Vries J. X., Zimmerman R., Augustin J. Anticoagulant and lipolytic effects of a low molecular weight heparin fraction. Thrombosis Research 1985; 39: 683–692
   PubMed Web of Science ®Google Scholar
• Harenberg J., Würzner B., Zimmerman R., Schettler G. Bioavailability and antagonization of the low molecular weight heparin, CY 216, in man. Thrombosis Research 1986; 44: 549–554
   PubMed Web of Science ®Google Scholar
• Holford N. H. G. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clinical Pharmacokinetics 1986; 11: 483–504
   PubMed Web of Science ®Google Scholar
• Holford N. H. G., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 1981; 6: 429–453
   PubMed Web of Science ®Google Scholar
• Holford N. H. G., Sheiner L. B. Kinetics of pharmacological response. Pharmacology and Therapeutics 1982; 16: 143–166
   PubMed Web of Science ®Google Scholar
• Hull R. D., Raskob G. E., Pineo G. F., Green D., Trowbridge A. A., Elliot C. G., Lerner R. G., Hall J., Sparlin T., Bretell H. R., Norton J., Carter C. J., George R., Merli G., Ward J., Mayo W., Rosenbloom D., Brant. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine 1992; 326: 975–982
   PubMed Web of Science ®Google Scholar
• Kakkar V. V., Djazaeri B., Fox J., Fletcher M., Scully M. F., Westwick J. Low molecular weight heparin and prevention of post-operative deep vein thrombosis. British Medical Journal 1982; 284: 375–379
   PubMed Web of Science ®Google Scholar
• Kandrotas R. J. Heparin pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics 1992; 22: 359–374
   PubMed Web of Science ®Google Scholar
• Lane D. A., Macgregor I. R., Vauross M., Calle G., Kakkar V. V. Molecular weight dependence of the anticoagulant properties of heparin after intravenous and subcutaneous administration of fractionated heparins to man. Thrombosis Research 1979; 16: 651–662
   PubMed Web of Science ®Google Scholar
• Matzsch T., Bergqvist D., Fredin H., Hedner U., Lindhagen A., Nistor L. Comparison of the thromboprophylatic effect of a low molecular heparin versus dextran in total hip replacement. Thrombosis and Haemorrhagic Disorders 1991; 1: 25–29
   Google Scholar
• McPherson G. A. Computer assisted analysis of complex concentration-response data. Journal of Pharmacological Methods 1985; 13: 125–134
   PubMedGoogle Scholar
• Pedraz J. L., Begona C., Smithers J. A., Thompson G. A. Pharmacokinetic-pharmacodynamic modelling: time-dependent protein binding—an alternative interpretation of clockwise and counterclockwise hysteresis. Journal of Pharmaceutical Sciences 1992; 81: 232–236
   PubMed Web of Science ®Google Scholar
• Powers W. F., Abbrecht P. J., Covell D. G. Systems and microcomputer approach to anticoagulant therapy. Institute of Electrical and Electronic Engineers Transactions. Biomedical Engineering 1980; 27: 520–523
   Google Scholar
• Rostin M., Montastruc J. L., Houin G., D'Azemar P. O., Bayrou B., Boreu B. Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. Fundamentals of Clinical Pharmacology 1990; 4: 17–23
   PubMed Web of Science ®Google Scholar
• Sandset P. M., Abildgaard U., Larsen L. M. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thrombosis Research 1988; 50: 803–813
   PubMed Web of Science ®Google Scholar
• Schran H. F., Bitz D. W., Diserio F. J., Hirsch J. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. Thrombosis Research 1983; 31: 51–67
   PubMed Web of Science ®Google Scholar
• Siegbahn A., Y-Hassan S., Boberg J., Bylund H., Neerstrand H. S., Ostergaard P., Hender U. Subcutaneous treatment of deep vein thrombosis with low molecular weight heparin. A dose finding study with LMWH-NOVO. Thrombosis Research 1989; 55: 767–778
   PubMed Web of Science ®Google Scholar
• Spector W. S. Handbook of Biological Data, W. S. Spector. Saunders, Philadelphia 1956; 340
   Google Scholar
• Thomas D. P., Merton R. E., Lewis W. E., Barrowcliffe T. W. Studies in man and experimental animals of a low molecular weight heparin fraction. Thrombosis and Haemostasis 1981; 45: 214–218
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P. Novel deconvolution method for linear pharmacokinetic systems with polyexponential input response. Journal of Pharmaceutical Sciences 1980a; 69: 312–318
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen. An algorithm and computer program for deconvolution in linear pharmacokinetics. Journal of Pharmacokinetics of Biopharmaceutics 1980b; 8: 463–481
   PubMedGoogle Scholar
• Whitfield L. R., Levy G. Pharmacokinetics of heparin V:in vivo and in vitro factors affecting the relationship between concentration and anticoagulant effect of heparin in rat plasma. Journal of Pharmaceutical Sciences 1983; 72: 1141–1146
   PubMed Web of Science ®Google Scholar
• Yin E. T., Wessler S., Butler J. Y. Plasma heparin: a unique, practical, submicrogram-sensitive assay. Journal of Laboratory and Clinical Medicine 1973; 81: 298–310
   PubMed Web of Science ®Google Scholar